Table 2.

Predictive significance of clinicopathologic variables in stage III colon cancer patients

FeatureN1, N2*HR (95% CI)P
Total851, 3050.76 (0.61-0.96)0.02
Age (y)
    ≤65242, 1820.85 (0.62-1.17)0.63
    >65609, 1230.68 (0.47-0.97)0.03
Sex
    Male400, 1620.81 (0.60-1.10)0.31
    Female451, 1430.71 (0.50-1.00)0.048
Site
    Proximal476, 1440.71 (0.56-1.05)0.13
    Distal380, 1560.70 (0.50-0.98)0.04
Grade
    Well/moderate659, 2370.74 (0.57-0.96)0.02
    Poor197, 630.84 (0.52-1.34)0.76
T stage
    T1-T3639, 2430.87 (0.67-1.13)0.35
    T4212, 620.46 (0.28-0.74)0.002
Nodal involvement
    N1562, 2090.74 (0.55-0.99)0.04
    N2289, 960.70 (0.49-1.01)0.13
Mucinous
    Yes223, 810.64 (0.42-0.98)0.04
    No628, 2240.88 (0.67-1.16)0.36
Vascular invasion
    Yes600, 2160.62 (0.42-0.93)0.02
    No256, 840.80 (0.60-1.05)0.20
TILs
    Yes114, 550.22 (0.10-0.46)<0.001
    No737, 2500.84 (0.66-1.07)0.29
Perforation
    Yes69, 280.21 (0.07-0.61)0.004
    No782, 2770.82 (0.65-1.04)0.13
  • * N1 = surgery alone; N2 = 5-FU chemotherapy.

  • Survival of patients treated with 5-FU chemotherapy versus treatment by surgery alone.